Gene expression signatures of BRCAness and tumor inflammation define subgroups of early-stage hormone receptor-positive breast cancer patients.

CONCLUSIONS: BRCA-related DNA repair deficiency and suppressed tumor immune responses may be clinically relevant predictors of endocrine therapy complementing treatment options in subgroups of hormone-sensitive early breast cancer.
PMID: 33008814 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - October 1, 2020 Category: Cancer & Oncology Authors: Schroth W, Büttner FA, Kandabarau S, Hoppe R, Fritz P, Kumbrink J, Kirchner T, Brauer HA, Ren Y, Henderson DA, Madden SF, Sauer G, Fehm T, Wallwiener D, Fasching PA, Mürdter TE, Schwab M, Tamoxifen Ai Clinicians Group G, Brauch H Tags: Clin Cancer Res Source Type: research